CannaBiz Invest Asia

Start:
Aug 29, 2019, 9:00 AM
End:
Aug 30, 2019, 1:00 PM

About CannaBiz Invest Asia

CMT's CannaBiz Invest Asia Summit on 29-30 August, 2019 in Bangkok, zooms in on the legal and commercial aspects of medical and industrial cannabis market in Asia vis-à-vis government regulations, investments, cultivation and value added products.
With more Asian countries starting to legalise medical and industrial cannabis use, major cannabis product manufacturers will convene in Bangkok for a timely summit to share insights on this new market.
Aurora Cannabis shares insights on Global Cannabis Market Outlook & Investment Landscape. Day 1 also features sessions from cannabis producers – CannAcubed presenting a case study on 'China's Industrial Hemp Cultivation & Value Chain Investment' and Elixinol
Global providing the 'Growth Outlook for Hemp Foods, Protein & the CBD Market in Japan & Globally'. Coffee break sponsor – Medipharm Labs will speak on Australia's Role in APAC Medical Cannabis Market.

Organised by Centre for Management Technology (CMT), the program also features sessions
on:
 The Future of Sustainable Fashion & Hemp Fibres Industry - Kingdom Holdings
 "Green Green Profits" - The Cultivation of Outdoor Medical Cannabis as a Business Model for Asia - Jacana Holdings
 Commercialisation of Plant-Derived Cannabinoid Prescription Medicines to Meet Global Demand - MGC Pharmaceuticals
 Pharmaceutical Development in Man-Made Cannabinoids - Akseera Pharma

In addition, MYM Nutraceuticals, Helius Therapeutics and Cannex Capital join a panel discussion on 'Accessing Capital Markets for Cannabis Investments – Options & Challenges'.

Meet exhibitors Shenzhen Number Energy Saving Corporation and Blue Sky Biologicals among others at the event. For exhibition details, email [email protected]

Speakers

Tamir Gedo
CEO BOL Pharma Ltd
Jahan Peston Jamas
Paul Benhaim
CAM BATTLEY
Chief Corporate Officer Aurora Cannabis Inc.
Manit Patel
Chief Executive Officer Akseera Pharma Corp
View More (10)
Glenn Davies
Co-Founder & Group CEO CannAcubed
Andy Chan
CFO Kingdom Holdings Limited
Markus Hoffmann
VP of Business Development Jacana
Blaise Bratter
Australia Operations Manager MGC Pharmaceuticals Limited
Atthachai Homhuan
Manager, Regulatory Affairs Tilleke & Gibbins International Ltd
Erick Factor
Executive Chairman & Founder MYM Nutraceuticals
Preet Marwaha
CEO Blue Sky Biologicals
Paul Manning
Co founder and Excutive Director Helius Therapeutics
Khwanchai Visithanon
Director Dept of Thai Traditional and Alternative Medicine, Ministry of Health

Partners

Weed World
Infuzes
Phyllo AI
420group
Whole Plant Extract

Agenda

Summit Day 1 29 Aug, 2019 - Thursday
08:00
Morning Registrations & Coffee
09:00
Chairman’s Welcome & Introduction
09:10
INTEGRATION OF MEDICAL CANNABIS IN THAI TRADITIONAL MEDICINE - A BALANCING GAME
Research updates and plans moving forward
Raw materials sourcing & cultivation plans
Future patient access criteria
Dr. Khwanchai Visithanon, Director
Dept of Thai Traditional and Alternative Medicine, Ministry of Health
09:40
UNDERSTANDING THE MEDICAL CANNABIS INVESTMENT LANDSCAPE & REGULATORY HURDLES IN THAILAND
Who can invest and the value chain for participation
What licenses and permits are required and which authorities to seek approval?
Dissecting the regulations from imports of seeds/strains to cultivation, extraction & refining to distribution, orphan drugs & etc
Intellectual Property consideration for cannabis investment in Thailand
Dr. Atthachai Homhuan, Manager, Regulatory Affairs
Tilleke & Gibbins International Ltd
10:10
CHINA – INDUSTRIAL HEMP CULTIVATION & VALUE CHAIN INVESTMENT CASE STUDY
Access to seeds varieties & cultivation investment challenges
CBD Oil extraction and value addition
Traceability and Compliance in the Cannabis Industry: Preparing for International Import and Export
Growth potential in China
Mr. Glenn Davies, Co-Founder & Group CEO
CannAcubed Pte Ltd
10:40
Networking Refreshment
11:10
GLOBAL CANNABIS MARKET OUTLOOK & INVESTMENT LANDSCAPE
Unlocking the cannabis market potential & challenges facing investors
Cam Battley, Chief Corporate Officer
Aurora Cannabis Inc.
11:40
FROM FARM TO PHARMACEUTICAL PRODUCTS – ISRAEL’S EXPERIENCE
Importance of clinical trial for medical cannabis
Will medical cannabis exports be a cash cow for Israel?
How will it impact the global cannabis market?
Dr. Tamir Gedo, CEO
BOL Pharma Ltd
12:10
GROWTH OUTLOOK FOR HEMP FOODS, PROTEIN & THE CBD MARKET IN JAPAN & GLOBALLY
Mr. Paul Benhaim, CEO
Elixinol Global Ltd
12:40
Networking Lunch
13:45
Afternoon Chairman’s Introduction
13:50
ACCESSING CAPITAL MARKETS FOR CANNABIS INVESTMENTS – OPTIONS & CHALLENGES
Panelists:
Erick Factor, Executive Chairman & Founder
MYM Nutraceuticals
Paul Manning, Co founder and Excutive Director
Helius Therapeutics
Anthony Dutton, CEO
Cannex Capital
14:20
CANNABIS LEGISLATION IN NEW ZEALAND: REFLECTIONS ON GOVERNMENT EFFORTS TO DESIGN WORLD-LEADING MEDICINAL CANNABIS & FULL LEGALISATION
Recent developments in New Zealand include the passing of Medicinal Cannabis legislation in 2018 and the current drafting of legislation for full legalisation that will be the subject of a national referendum in 2020. New Zealand is an advanced economy with a small population and strong democracy. Starting after other jurisdictions, the country has been able to take the best of existing examples around the globe to design world-leading legislation and regulations for the legal production and use of cannabis.
Mr. Manu Caddie, CEO
Hikurangi Cannabis Company
14:50
OUTLOOK OF THE MEDICAL CANNABIS INDUSTRY IN AUSTRALIA
Australian Cannabis Laws at a Glance
Medical cannabis research, production & clinical trials update
Economics of production for local and export markets
Medical professional’s attitude towards medical cannabis, prescription and patient access challenges
15:20
Networking Refreshment
15:50
HEMP: BEYOND CBD & THC, A WHOLE PLANT MODEL
A plant that we have had a 5000+ year history with it gaining worldwide acceptance once again and the entire benefits of this plant are still mostly unknown. The hemp plant delivers tremendous benefits in the areas of Food, Fibre and Medicine and we will explore all of these areas with a focus on the medicine, which we have only begun to truly understand.
Preet Marwaha, CEO
Blue Sky Biologicals
16:20
THE FUTURE OF SUSTAINABLE FASHION & HEMP FIBRES INDUSTRY
Mr. Andy Chan, CFO
Kingdom Holdings Limited
16:50
CBD – THE NEXT BIG THING IN BEAUTY?
Emerging trends & market size for CBD infused beauty & wellness products
How regulation will affect the CBD beauty industry & supply chain?
Formulation & standards
Marketing & distribution channels
17:20
End of Day One

Summit Day 2
30 Aug, 2019 - Friday
09:00
Chairman’s Introduction
09:10
INDUSTRIAL AND MEDICAL CANNABIS INVESTMENT IN INDIA – SCIENTIFIC AND LEGAL PERSPECTIVE
Cannabis – India’s next Green revolution & what the future holds?
BOHECO’s scientific, policy & commercial endeavours to bring Hemp into the mainstream in India
Innovations with Industrial Hemp & Medicinal Cannabis – What’s in store from an India & Asia horizon
Navigating legal landscape moving forward
Mr. Jahan Peston Jamas, Co-founder & & Director, Strategic Development and Collaborations
Bombay Hemp Company Private Limited (BOHECO)
09:40
“GREEN GREEN PROFITS” - THE CULTIVATION OF OUTDOOR MEDICAL CANNABIS AS A BUSINESS MODEL FOR ASIA
Cultivation Methods and Facility Design - Outdoor vs. Indoor, Advantages and Disadvantages
Sustainability - Why it should be an integral part of your business model
Quality Assurance - How outdoor grown medical cannabis can meet and exceed international quality standards
Mr. Markus Hoffmann, VP of Business Development
Jacana Holdings Inc.
10:10
LATEST EXTRACTION & REFINING TECHNOLOGIES - PERSPECTIVE FROM BIOTECH COMPANIES
10:40
Networking Refreshment
11:10
CANNABIS SEEDS & STRAINS SELECTION
Effect of Variety on Crop Yield and Cannabinoid Content
Plant variety protection
11:40
COMMERCIALIZATION OF PLANT-DERIVED CANNABINOID PRESCRIPTION MEDICINES TO MEET GLOBAL DEMAND
Plans beyond CannEpil
Ensuring supply & ensuring consistency in plant-based raw materials for commercial production
Clearing regulatory approvals for global distribution
Mr. Blaise Bratter, Australia Operations Manager
MGC Pharmaceuticals Ltd
12:10
PHARMACEUTICAL DEVELOPMENT IN MAN-MADE CANNABINOIDS
Genetic engineering and the prospect of man-made cannabinoids
Is it a more economical & regulatory-friendly alternative to natural CBD?
Mr. Manit Patel, Chief Executive Officer
Akseera Pharma Corp
12:40
Final Discussion followed by Closing Lunch